Tumor necrosis factor-α–induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line
Authors:
- Toshinari TakamuraTTToshinari Takamura
- 1 November 2006
- journal article
- Published by Elsevier in Metabolism
- Vol. 55 (11) , 1464-1472
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- The selective inhibition of nitric oxide production in the avian macrophage cell line HD11Veterinary Immunology and Immunopathology, 2005
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined dietBiochemical and Biophysical Research Communications, 2004
- Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue AccumulationArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-α–activated human peritoneal mesothelial cellsKidney International, 2003
- Obesity and insulin resistanceJournal of Clinical Investigation, 2000
- The Plasminogen–Activating System in Hepatic Stellate CellsHepatology, 1996
- Mitogen-activated protein kinase activation in hepatocyte growth factor-stimulated rat hepatocytes: Involvement of protein tyrosine kinase and protein kinase CHepatology, 1996
- Tumor Necrosis Factor α-induced Phosphorylation of Insulin Receptor Substrate-1 (IRS-1)Journal of Biological Chemistry, 1995
- Effects of a New Oral Hypoglycaemic Agent (CS-045) on Metabolic Abnormalities and Insulin Resistance in Type 2 DiabetesDiabetic Medicine, 1994